jRCT2051220044Recruitment Completed
Untitled Trial
A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP 1 receptor agonist.(NN1535 4592) (COMBINE 2) (COMBINE 2)
Novo Nordisk Pharma Ltd.Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
- Disease/Condition
- type 2 diabetes
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Novo Nordisk Pharma Ltd.
- Location
- Brazil;Canada;China;France;Greece;Hungary;Israel;Russia;Slovenia;Sweden;Switzerland;Taiwan,;United S
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2051220044
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2051220044 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk Pharma Ltd. and is currently Recruitment Completed. The study focuses on type 2 diabetes.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.